Wed, 15 July 2015
Motley Fool's Michael Douglass and Todd Campbell shed light on how Celgene's deal-making frenzy positions it as a potential MS leader and offer up insight into how to value immuno-oncology stocks. |
Tue, 14 July 2015
As Comic-Con wraps up, movie goers are sitting on the edge of their seats waiting for the next flick to thrill them once again. |